|
The Company
Augurex Life Sciences Corp. develops biomarker technologies to screen people for
diseases that when identified can be promptly treated, thereby delivering the
benefit of earlier detection and greater treatment success. Biomarker screening
tools can also be used to optimize a person’s therapy by predicting which treatment
will personally offer them maximum therapeutic benefit while minimizing their side effects.
Hence our signature; Identify, Optimize, Personalize.
Augurex’s lead technology, AGX-020 is a novel biomarker of
arthritis which is being developed as a simple blood test to help doctors accurately assess
the degree of disease activity, thereby providing an alternative to subjective clinical disease
measures. Additionally, AGX-020 may provide physicians with a tool to manage their rheumatoid
arthritis patients more effectively by determining which patients are responding to biological
therapy.
Augurex identifies early-stage biomarkers and focuses on their scientific and clinical advancement
by integrating novel research and development methods in partnership with scientific, clinical and
commercial collaborators. The synergies gained by these partnerships allow for an accelerated
understanding of the biomarker’s clinical uses and rapidly provide physician and patient
access to the blood test.
|